Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen

被引:6
|
作者
Trifunov, Selena [1 ,6 ]
Natera-de Benito, Daniel [1 ,2 ]
Carrera-Garcia, Laura [1 ,2 ]
Codina, Anna [1 ]
Exposito-Escudero, Jesica [1 ,2 ]
Ortez, Carlos [1 ]
Medina, Julita [4 ]
Torres Alcala, Soraya [3 ]
Bernal, Sara [5 ,6 ]
Alias, Laura [5 ,6 ]
Badosa, Carmen [1 ]
Balsells, Sol [7 ]
Alcolea, Daniel [3 ]
Nascimento, Andres [1 ,2 ,6 ]
Jimenez-Mallebrera, Cecilia [1 ,6 ,8 ]
机构
[1] Inst Recerca St Joan De Deu, Appl Res Neuromuscular Dis, Barcelona, Spain
[2] Hosp San Juan Dios, Dept Neurol, Neuromuscular Unit, Barcelona, Spain
[3] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Hosp Santa Creu & St Pau, Dept Neurol, Barcelona, Spain
[4] Hosp St Joan De Deu, Rehabil & Phys Unit Dept, Barcelona, Spain
[5] Univ Autonoma Barcelona, Inst Invest Biomed St Pau Hosp St Pau, Dept Genet, Barcelona, Spain
[6] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain
[7] Inst Recerca St Joan De Deu, Stat Dept, Barcelona, Spain
[8] Univ Barcelona, Dept Genet Microbiol & Stat, Barcelona, Spain
关键词
Biomarkers; cerebrospinal fluid; nusinersen; response predictors; serum; spinal muscular atrophy; SHAM CONTROL; EXPRESSION; EXOSOMES;
D O I
10.3233/JND-230012
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Three therapeutic strategies have radically changed the therapeutic scenario for spinal muscular atrophy (SMA). However, therapeutic response differs between individuals. There is a need to identify biomarkers to further assess therapeutic response and to better understand which variables determine the extent of response. Methods: We conducted a study using an optimized digital droplet PCR-based method for the ultra-sensitive detection of SMN transcript in serum EVs from SMA 2 individuals treated with nusinersen over 14 months. In parallel, we investigated levels of serum and CSF neurofilament heavy chain (pNF-H) in the same cohort. Results: Expression of flSMN transcript in EVs of SMA 2 individuals prior to nusinersen was lower than in controls (0.40 vs 2.79 copies/ul; p < 0.05) and increased after 14 months of nusinersen (0.40 vs 1.11 copies/ul; p < 0.05). The increase in flSMN with nusinersen was significantly higher in younger individuals (p < 0.05). Serum pNF-h was higher in non-treated individuals with SMA 2 than in controls (230.72 vs 22.88 pg/ml; p < 0.05) and decreased with nusinersen (45.72 pg/ml at 6 months, 39.02 pg/ml at 14 months). CSF pNF-h in SMA 2 individuals also decreased with nusinersen (248.04 pg/ml prior to treatment, 197.10 pg/dl at 2 months, 104.43 pg/dl at 6 months, 131.03 pg/dl at 14 months). Conclusions: We identified an increase of flSMN transcript in serum EVs of SMA 2 individuals treated with nusinersen that was more pronounced in the younger individuals. Our results indicate that flSMN transcript expression in serum EVs is a possible biomarker in SMA to predict or monitor the response to treatment.
引用
收藏
页码:653 / 665
页数:13
相关论文
共 50 条
  • [41] The gene copy ratios of SMN1/SMN2 in Japanese carriers with type I spinal muscular atrophy
    Tran, TD
    Kroepfl, T
    Saito, M
    Nagura, M
    Ichiseki, H
    Kubota, M
    Toda, T
    Sakakihara, Y
    BRAIN & DEVELOPMENT, 2001, 23 (05): : 321 - 326
  • [42] Antisense oligomer mediated retention of SMN2 intron and exon 7 leads to a novel SMN transcript and increased functional SMN protein in Spinal Muscular Atrophy fibroblasts
    Mitrpant, C.
    Price, L.
    Johnsen, R. D.
    Burghes, A. H.
    Fletcher, S.
    Wilton, S. D.
    NEUROMUSCULAR DISORDERS, 2011, 21 (9-10) : 685 - 685
  • [43] Carboxylic acid derivatives of histone deacetylase inhibitors induce full length SMN2 transcripts: a promising target for spinal muscular atrophy therapeutics
    Dayangac-Erden, Didem
    Bora-Tatar, Gamze
    Dalkara, Sevim
    Demir, Ayhan S.
    Erdem-Yurter, Hayat
    ARCHIVES OF MEDICAL SCIENCE, 2011, 7 (02) : 230 - 234
  • [44] Therapeutic Role of Nusinersen on Respiratory Progression in Pediatric Patients With Spinal Muscular Atrophy Type 2 and Nonambulant Type 3
    Trucco, Federica
    Ridout, Deborah
    Weststrate, Harriet
    Scoto, Mariacristina
    Rohwer, Annemarie
    Coratti, Giorgia
    Main, Marion L.
    Mayhew, Anna G.
    Montes, Jacqueline
    De Sanctis, Roberto
    Pane, Marika
    Pera, Maria Carmela
    Sansone, Valeria A.
    Albamonte, Emilio
    D'Amico, Adele
    Bruno, Claudio
    Messina, Sonia S.
    Childs, Anne-Marie
    Willis, Tracey
    Ong, Min T.
    Servais, Laurent
    Majumdar, Anirban
    Hughes, Imelda
    Marini-Bettolo, Chiara
    Parasuraman, Deepak
    Gowda, Vasantha L.
    Baranello, Giovanni
    Bertini, Enrico S.
    De Vivo, Darryl C.
    Darras, Basil T.
    Day, John W.
    Mayer, Oscar
    Zolkipli-Cunningham, Zarazuela
    Finkel, Richard S.
    Mercuri, Eugenio
    Muntoni, Francesco
    NEUROLOGY-CLINICAL PRACTICE, 2024, 14 (03)
  • [45] Longitudinal changes in electrophysiological findings caused by nusinersen administration in patients with spinal muscular atrophy type 2 or type 3
    Arahata, Y.
    Ishiyama, A.
    Takeshita, E.
    Shimizu-Motohashi, Y.
    Komaki, H.
    Sasaki, M.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S190 - S190
  • [46] A RETROSPECTIVE COHORT STUDY OF CHILDREN WITH SPINAL MUSCULAR ATROPHY TYPE 2 RECEIVING ANESTHESIA FOR INTRATHECAL ADMINISTRATION OF NUSINERSEN
    Bielsky, Alan R.
    Yaster, Myron
    Fuhr, Peter G.
    Parsons, Julie A.
    ANESTHESIA AND ANALGESIA, 2018, 126 (04): : 501 - 501
  • [47] A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen
    Bielsky, Alan R.
    Fuhr, Peter G.
    Parsons, Julie A.
    Yaster, Myron
    PEDIATRIC ANESTHESIA, 2018, 28 (12) : 1105 - 1108
  • [48] The Impact of Nusinersen and Risdiplam on Motor Function for Spinal Muscular Atrophy Type 2 and 3: A Meta-Analysis
    Chen, Bo
    Gong, Yuanlin
    Zhou, Tengteng
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2024, 34 (08): : 948 - 955
  • [49] Effectiveness of Nusinersen in Type 1, 2 and 3 Spinal Muscular Atrophy: Croatian Real-World Data
    Belancic, Andrej
    Strbad, Tea
    Stiglic, Marta Kucan
    Vitezic, Dinko
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (08)
  • [50] Neurofilament light chain and profilin-1 dynamics in 30 spinal muscular atrophy type 3 patients treated with nusinersen
    Musso, G.
    Bello, L.
    Capece, G.
    Bozzoni, V.
    Caumo, L.
    Sabbatini, D.
    Zangaro, V.
    Sogus, E.
    Cosma, C.
    Petrosino, A.
    Soraru, G.
    Plebani, M.
    Pegoraro, E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (10)